ストックスクリーナーアプリを入手
12.65
0.79%
-0.005
前日終値:
$12.65
開ける：
$12.54
24時間の取引高:
36,316
Relative Volume:
0.03
時価総額：
$748.40M
収益：
$122.29M
当期純損益:
$122.31M
株価収益率:
5.8754
EPS:
2.1539
ネットキャッシュフロー:
$12.00M
1週間 パフォーマンス:
-8.13%
1か月 パフォーマンス:
+13.99%
6か月 パフォーマンス:
+54.56%
1年 パフォーマンス:
+37.53%
1日の値動き範囲:
$12.54
$12.74
1週間の範囲:
$12.37
$14.27
52週間の値動き範囲:
$7.16
$14.27
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
12.66 | 741.89M | 122.29M | 122.31M | 12.00M | 2.1539 |
VRTX
Vertex Pharmaceuticals Inc
|
452.56 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
615.18 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.02 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
285.41 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.23 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 開始されました | BTIG Research | Buy |
| 2025-07-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-08 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 開始されました | Guggenheim | Buy |
| 2024-09-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-24 | 繰り返されました | Maxim Group | Buy |
| 2024-04-02 | 繰り返されました | Maxim Group | Buy |
| 2024-03-12 | 開始されました | William Blair | Outperform |
| 2023-03-17 | 開始されました | Maxim Group | Buy |
すべてを表示
Zevra Therapeutics Inc (ZVRA) 最新ニュース
ZVRA Price Today: Zevra Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Zevra Therapeutics Q2 2025 Earnings Preview - MSN
ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
ZVRA News | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
ZVRA Maintained by Canaccord Genuity -- Price Target Stays at $2 - GuruFocus
Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $29 - Moomoo
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - The Manila Times
Press Release: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition - Moomoo
ZVRA Upgraded by Guggenheim -- Price Target Raised to $29 - GuruFocus
ZVRA Maintains Rating by Maxim Group -- Price Target Raised to $35.00 - GuruFocus
A Quick Look at Today's Ratings for Zevra Therapeutics(ZVRA.US), With a Forecast Between $25 to $34 - Moomoo
Zevra Therapeutics Is Maintained at Buy by Maxim Group - Moomoo
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Guggenheim raises Zevra Therapeutics price target on patent extension - Investing.com UK
Guggenheim raises Zevra Therapeutics price target on patent extension By Investing.com - Investing.com Nigeria
ZVRA Reiterates by BTIG -- Price Target Raised to $27.00 - GuruFocus
Liquidity Mapping Around (ZVRA) Price Events - Stock Traders Daily
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat? - Yahoo Finance
BTIG raises Zevra Therapeutics price target to $27 on patent filing - Investing.com Nigeria
ZVRA Maintains Buy Rating -- Price Target Raised to $29.00 by Ca - GuruFocus
BTIG raises Zevra Therapeutics price target to $27 on patent filing By Investing.com - Investing.com India
ZVRA stock hits its highest levels in nearly 5 years – what’s driving this sharp rally today? - MSN
ZVRA Maintains by Citizens -- Price Target Raised to $25.00 - GuruFocus
Zevra Therapeutics stock price target raised to $29 by Canaccord on patent extension - Investing.com South Africa
H.C. Wainwright reiterates Zevra Therapeutics stock rating on patent extension - Investing.com Nigeria
Citizens raises Zevra Therapeutics price target on patent exclusivity By Investing.com - Investing.com Nigeria
Citizens raises Zevra Therapeutics price target on patent exclusivity - Investing.com
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
ZVRA Maintained by Cantor Fitzgerald -- Price Target Raised to $34 - GuruFocus
Zevra Therapeutics (ZVRA) Files New Patent for Miplyffa - GuruFocus
Why is Zevra Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Why is Zevra Therapeutics stock surging today? - Investing.com
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug - Yahoo Finance
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041 - Yahoo Finance
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA - The Manila Times
Zevra moves to list rare disease drug MIPLYFFA in FDA Orange Book - Stock Titan
Zevra Therapeutics Inc (ZVRA) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
0.10%
大文字化:
|
ボリューム (24 時間):